Stephen Mandel Blueprint Medicines Corp Transaction History
Lone Pine Capital LLC
- $12.7 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding BPMC
# of Institutions
313Shares Held
60.6MCall Options Held
634KPut Options Held
691K-
Black Rock Inc. New York, NY6.45MShares$695 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.31MShares$680 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.25MShares$674 Million0.07% of portfolio
-
Wellington Management Group LLP Boston, MA4.18MShares$450 Million0.07% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.5MShares$269 Million6.2% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $6.44B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...